Mark Gurney
President
Pharmaceutical
Epigen BioSciences, Inc.
Canada
Biography
Dr. Mark Gurney, is the Chairman and CEO of Tetra Discovery Partners. Dr. Gurney previously was Senior Vice President of Drug Discovery and Development for deCODE genetics, Inc. where he led two CRO businesses which grew in annual sales from $13 to $22 million. Dr. Gurney developed 3 Decode compounds through human Phase I clinical trials and also developed a client drug to treat spinal muscular atrophy that was licensed to Pfizer for $70 million and recently entered human Phase II clinical trials. Dr. Gurney was named one of two leading inventors in the field of Alzheimer’s disease therapeutics by the global law firm Griffith Hack. He has authored 116 peer-reviewed papers that have been cited over 18,000 times and holds 35 issued patents. Dr. Mark Gurney, is the Chairman and CEO of Tetra Discovery Partners. Dr. Gurney previously was Senior Vice President of Drug Discovery and Development for deCODE genetics, Inc. where he led two CRO businesses which grew in annual sales from $13 to $22 million. Dr. Gurney developed 3 Decode compounds through human Phase I clinical trials and also developed a client drug to treat spinal muscular atrophy that was licensed to Pfizer for $70 million and recently entered human Phase II clinical trials. Dr. Gurney was named one of two leading inventors in the field of Alzheimer’s disease therapeutics by the global law firm Griffith Hack. He has authored 116 peer-reviewed papers that have been cited over 18,000 times and holds 35 issued patents.
Research Interest
Drug Discovery and Development Pharmaceutical Technology and Biopharmaceutics Pharmaceutical Analysis
